Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis

Executive Summary

• Thiogenesis Therapeutics reported encouraging interim data from its Phase 2 MELAS trial, showing TTI‑0102 is well tolerated and demonstrates biomarker improvements.
• The company outlined next steps: filing an IMPD for a pivotal Phase 3 MELAS study in Europe (2026) and advancing IND‑cleared Phase 2 trials for Leigh syndrome spectrum (early 2026) and a planned Phase 3 trial for nephropathic cystinosis.
• Positive interim findings are expected to support dosing strategies across multiple mitochondrial disease programs and may enhance the company’s valuation as it moves toward pivotal studies.

Key Details

• Interim MELAS Trial Data – Blinded analysis of first 3 months; 9 patients (6 on TTI‑0102, 3 placebo).
• Five active patients (>70 kg) remain: 2 on TTI‑0102, 3 on placebo.
• Four lighter patients (<50 kg) withdrew due to dose‑dependent side effects, prompting dosing regimen refinement.
• Safety/Tolerability – No new safety signals; tolerability consistent with Phase 1 data in healthy adults.
• Biomarker/Efficacy Signals – Confidential interim biomarker improvements indicating mitochondrial antioxidant activity; full data pending publication (early 2026).
• Regulatory & Development Plans
• MELAS: Final 6‑month data expected Jan 2026; intent to file IMPD for Phase 3 trial in Europe during 2026.
• Leigh Syndrome Spectrum: FDA accepted IND (June 2025); IRB approval and manufacturing underway; Phase 2 start projected early 2026 with dosing adjustments based on MELAS data.
• Nephropathic Cystinosis: Planning IND for a non‑inferiority Phase 3 trial comparing TTI‑0102 to standard cysteamine therapy; aims for once‑daily dosing and improved side‑effect profile.
• Market Opportunity – MELAS prevalence ~4.1 per 100,000 worldwide; Leigh syndrome ~1/40,000 live births; nephropathic cystinosis ≈1,300 U.S. patients (similar in Europe).
• CEO Quote – “The interim data are highly encouraging… they validate our therapeutic approach for multiple conditions associated with mitochondrial dysfunction.” – Dr. Patrice Rioux, CEO.

Notable Quotes

“Enrollment has now met the required thresholds for both dose discovery and proof‑of‑concept objectives. These results also reinforce our strategy to advance TTI‑0102 into a pivotal Phase 3 study in MELAS and helps guide dosing across our broader mitochondrial and metabolic disease programs.” – Dr. Patrice Rioux, CEO

Materiality Assessment: Material – Positive (the interim data provide substantive evidence of efficacy/tolerability that materially advances the company’s clinical development roadmap).